Announcement • Jun 30
Eyebright Medical Technology (Beijing) Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Major Estimate Revision • Apr 29
Consensus EPS estimates fall by 15%, revenue upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from CN¥1.72b to CN¥1.76b. EPS estimate fell from CN¥2.52 to CN¥2.14 per share. Net income forecast to grow 59% next year vs 32% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥80.88 to CN¥73.55. Share price was steady at CN¥50.90 over the past week. Price Target Changed • Apr 24
Price target decreased by 9.1% to CN¥73.55 Down from CN¥80.88, the current price target is an average from 3 analysts. New target price is 38% above last closing price of CN¥53.12. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥2.37 for next year compared to CN¥1.40 last year. Reported Earnings • Apr 24
First quarter 2026 earnings: EPS misses analyst expectations First quarter 2026 results: EPS: CN¥0.46 (down from CN¥0.49 in 1Q 2025). Revenue: CN¥398.2m (up 12% from 1Q 2025). Net income: CN¥89.3m (down 3.5% from 1Q 2025). Profit margin: 22% (down from 26% in 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 13%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • Apr 23
Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, May 21, 2026 Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, May 21, 2026, at 14:00 China Standard Time. Location: The Company Headquarters' Meeting Room, Beijing China Announcement • Mar 30
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 New Risk • Mar 02
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 18% Last year net profit margin: 28% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 02
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥1.38 (down from CN¥2.05 in FY 2024). Revenue: CN¥1.48b (up 5.2% from FY 2024). Net income: CN¥265.4m (down 32% from FY 2024). Profit margin: 18% (down from 28% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.7%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Price Target Changed • Feb 14
Price target decreased by 13% to CN¥81.22 Down from CN¥93.16, the current price target is an average from 3 analysts. New target price is 36% above last closing price of CN¥59.50. Stock is down 40% over the past year. The company is forecast to post earnings per share of CN¥2.08 for next year compared to CN¥2.05 last year. Announcement • Dec 26
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Price Target Changed • Nov 14
Price target decreased by 12% to CN¥101 Down from CN¥115, the current price target is an average from 4 analysts. New target price is 56% above last closing price of CN¥64.83. Stock is down 32% over the past year. The company is forecast to post earnings per share of CN¥2.05 for next year compared to CN¥2.05 last year. Price Target Changed • Nov 03
Price target decreased by 7.2% to CN¥111 Down from CN¥120, the current price target is an average from 3 analysts. New target price is 72% above last closing price of CN¥64.62. Stock is down 31% over the past year. The company is forecast to post earnings per share of CN¥2.08 for next year compared to CN¥2.05 last year. Reported Earnings • Oct 30
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.39 (down from CN¥0.58 in 3Q 2024). Revenue: CN¥357.7m (down 8.2% from 3Q 2024). Net income: CN¥76.8m (down 30% from 3Q 2024). Profit margin: 22% (down from 28% in 3Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Jul 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Jun 30
Eyebright Medical Technology (Beijing) Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • May 29
Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, Jun 19, 2025 Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, Jun 19, 2025, at 14:00 China Standard Time. Location: The Company Headquarters' Meeting Room, Beijing China Buy Or Sell Opportunity • May 22
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 24% to CN¥75.06. The fair value is estimated to be CN¥94.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 67% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Reported Earnings • Apr 24
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: EPS: CN¥0.49 (down from CN¥0.54 in 1Q 2024). Revenue: CN¥357.2m (up 15% from 1Q 2024). Net income: CN¥92.6m (down 10% from 1Q 2024). Profit margin: 26% (down from 33% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 32%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥85.98, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥98.05 per share. Announcement • Mar 28
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Q1, 2025 Results on Apr 23, 2025 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025 Announcement • Jan 08
Eyebright Medical Technology (Beijing) Co., Ltd. Receives NMPA Class III Certificate for its Phakic Intraocular Lens Eyebright Medical Technology (Beijing) Co., Ltd. announced that Phakic intraocular lens, "Loong Crystal PR", has received Class III Medical Devices Certificate from the National Medical Products Administration ("NMPA"). The Loong Crystal PR intraocular lens is meticulously designed for the treatment of adult patients, providing effective correction or reduction of myopia ranging from -3.25D to -18.00D. This lens offers a tailored solution for individuals with varying degrees of myopia, ensuring optimal visual outcomes and enhancing patient satisfaction. Constructed from an advanced balanced acrylic material, the Loong Crystal PR incorporates a zero spherical separation design with a large optical zone and a double concave stable arch height structure. Upon implantation, it serves as a refractive element, significantly improving visual acuity while delivering high-quality postoperative results. This innovative design not only boosts optical performance but also elevates the overall visual experience, meeting the high expectations of patients for visual clarity. Eyebright Medical prioritizes technology and continuous innovation, aiming to deliver high-quality, safe, and reliable ophthalmic solutions. Through ongoing research and development, the company is dedicated to expanding the domestic ophthalmology landscape and enhancing the recognition of national brands in the industry. Announcement • Dec 27
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Fiscal Year 2024 Results on Apr 23, 2025 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report fiscal year 2024 results on Apr 23, 2025 Reported Earnings • Nov 03
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: EPS: CN¥0.58 (up from CN¥0.47 in 3Q 2023). Revenue: CN¥389.5m (up 49% from 3Q 2023). Net income: CN¥109.6m (up 23% from 3Q 2023). Profit margin: 28% (down from 34% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 1.7%. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥89.07, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥138 per share. Announcement • Sep 30
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥85.79, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥137 per share. New Risk • Sep 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (28% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change). Reported Earnings • Aug 22
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: EPS: CN¥0.56 (up from CN¥0.44 in 2Q 2023). Revenue: CN¥375.3m (up 73% from 2Q 2023). Net income: CN¥105.1m (up 24% from 2Q 2023). Profit margin: 28% (down from 39% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 74%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥79.04, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥122 per share. Announcement • Jun 29
Eyebright Medical Technology (Beijing) Co., Ltd. to Report First Half, 2024 Results on Aug 22, 2024 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report first half, 2024 results on Aug 22, 2024 Major Estimate Revision • Jun 11
Consensus EPS estimates fall by 38% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥0.634 to CN¥0.396. Revenue forecast unchanged from CN¥1.38b at last update. Net income forecast to grow 30% next year vs 48% growth forecast for Medical Equipment industry in China. Consensus price target up from CN¥91.78 to CN¥119. Share price fell 5.8% to CN¥76.34 over the past week. Price Target Changed • Jun 06
Price target decreased by 32% to CN¥145 Down from CN¥215, the current price target is an average from 3 analysts. New target price is 89% above last closing price of CN¥76.77. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥3.85 for next year compared to CN¥2.89 last year. New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (29% accrual ratio). Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Buy Or Sell Opportunity • Jun 05
Now 29% undervalued after recent price drop Over the last 90 days, the stock has fallen 47% to CN¥79.70. The fair value is estimated to be CN¥112, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 88% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 43% After last week's 43% share price decline to CN¥79.70, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 74% over the past three years. Announcement • Apr 19
Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, May 08, 2024 Eyebright Medical Technology (Beijing) Co., Ltd., Annual General Meeting, May 08, 2024, at 14:00 China Standard Time. Location: The Company Headquarters' Meeting Room, Beijing China Reported Earnings • Apr 18
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: EPS: CN¥0.98 (up from CN¥0.75 in 1Q 2023). Revenue: CN¥310.4m (up 64% from 1Q 2023). Net income: CN¥102.9m (up 31% from 1Q 2023). Profit margin: 33% (down from 41% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) missed analyst estimates by 3.0%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Apr 08
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥127. The fair value is estimated to be CN¥160, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 78% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Announcement • Mar 29
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Q1, 2024 Results on Apr 18, 2024 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report Q1, 2024 results on Apr 18, 2024 Buy Or Sell Opportunity • Mar 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 25% to CN¥128. The fair value is estimated to be CN¥161, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 29%. Revenue is forecast to grow by 78% in 2 years. Earnings are forecast to grow by 86% in the next 2 years. Announcement • Feb 24
Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) announces an Equity Buyback for CNY 40 million worth of its shares. Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) announces a share repurchase program. Under the program, the company will repurchase up to CNY 40 million. The shares will be repurchased at no more than CNY 229.37 per share. The purpose of the program is to use the repurchased shares for equity incentives or employee stock ownership plans. If the company fails to use the repurchased shares within 3 years of completion of the program, the unused shares will be cancelled. The company will use its own funds or self raised funds for the program. The plan will be valid for 12 months. Major Estimate Revision • Feb 13
Consensus EPS estimates fall by 12%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from CN¥1.21b to CN¥1.27b. EPS estimate fell from CN¥4.12 to CN¥3.63 per share. Net income forecast to grow 25% next year vs 33% growth forecast for Medical Equipment industry in China. Consensus price target broadly unchanged at CN¥223. Share price rose 9.5% to CN¥164 over the past week. Reported Earnings • Feb 07
Full year 2023 earnings released: EPS: CN¥2.89 (vs CN¥2.21 in FY 2022) Full year 2023 results: EPS: CN¥2.89 (up from CN¥2.21 in FY 2022). Revenue: CN¥951.4m (up 64% from FY 2022). Net income: CN¥304.4m (up 31% from FY 2022). Profit margin: 32% (down from 40% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥134, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥148 per share. Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Feng Jiang was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Dec 29
Eyebright Medical Technology (Beijing) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: EPS: CN¥0.85 (up from CN¥0.72 in 3Q 2022). Revenue: CN¥261.3m (up 55% from 3Q 2022). Net income: CN¥88.8m (up 17% from 3Q 2022). Profit margin: 34% (down from 45% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Price Target Changed • Aug 23
Price target decreased by 8.1% to CN¥232 Down from CN¥253, the current price target is an average from 3 analysts. New target price is 47% above last closing price of CN¥158. Stock is down 19% over the past year. The company is forecast to post earnings per share of CN¥3.10 for next year compared to CN¥2.21 last year. New Risk • Aug 19
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 28% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 18
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: CN¥0.80 (up from CN¥0.61 in 2Q 2022). Revenue: CN¥217.1m (up 53% from 2Q 2022). Net income: CN¥84.8m (up 32% from 2Q 2022). Profit margin: 39% (down from 46% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates by 4.5%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Eyebright Medical Technology (Beijing) Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report first half, 2023 results on Aug 18, 2023 Major Estimate Revision • Apr 27
Consensus revenue estimates decrease by 10%, EPS upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥962.5m to CN¥864.6m. EPS estimate increased from CN¥3.12 to CN¥3.16 per share. Net income forecast to grow 47% next year vs 35% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥242 unchanged from last update. Share price rose 2.1% to CN¥221 over the past week. Reported Earnings • Apr 19
First quarter 2023 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.75 (up from CN¥0.56 in 1Q 2022). Revenue: CN¥189.8m (up 45% from 1Q 2022). Net income: CN¥78.4m (up 34% from 1Q 2022). Profit margin: 41% (down from 45% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Price Target Changed • Nov 25
Price target increased to CN¥240 Up from CN¥214, the current price target is an average from 3 analysts. New target price is 14% above last closing price of CN¥211. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥2.34 for next year compared to CN¥1.63 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Jiang Feng was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 26
Third quarter 2022 earnings: EPS exceeds analyst expectations Third quarter 2022 results: EPS: CN¥0.72 (up from CN¥0.46 in 3Q 2021). Revenue: CN¥168.3m (up 42% from 3Q 2021). Net income: CN¥75.8m (up 55% from 3Q 2021). Profit margin: 45% (up from 41% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 29%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Reported Earnings • Aug 18
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: CN¥0.61 (up from CN¥0.53 in 2Q 2021). Revenue: CN¥141.7m (up 16% from 2Q 2021). Net income: CN¥64.5m (up 16% from 2Q 2021). Profit margin: 46% (in line with 2Q 2021). Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 3.6%. Over the next year, revenue is forecast to grow 60%, compared to a 26% growth forecast for the Medical Equipment industry in China. Price Target Changed • Apr 27
Price target decreased to CN¥212 Down from CN¥274, the current price target is an average from 5 analysts. New target price is 21% above last closing price of CN¥176. Stock is down 21% over the past year. The company is forecast to post earnings per share of CN¥2.38 for next year compared to CN¥1.63 last year. Reported Earnings • Apr 02
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.63 (up from CN¥1.08 in FY 2020). Revenue: CN¥433.1m (up 59% from FY 2020). Net income: CN¥171.3m (up 78% from FY 2020). Profit margin: 40% (up from 35% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.2%. Over the next year, revenue is forecast to grow 46%, compared to a 25% growth forecast for the industry in China. Reported Earnings • Feb 24
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.63 (up from CN¥1.08 in FY 2020). Revenue: CN¥433.1m (up 59% from FY 2020). Net income: CN¥171.3m (up 78% from FY 2020). Profit margin: 40% (up from 35% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 4.2%. Over the next year, revenue is forecast to grow 46%, compared to a 24% growth forecast for the industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.32 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥118.6m (up 52% from 3Q 2020). Net income: CN¥48.9m (up 57% from 3Q 2020). Profit margin: 41% (up from 40% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.48 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥121.9m (up 57% from 2Q 2020). Net income: CN¥55.4m (up 63% from 2Q 2020). Profit margin: 46% (up from 44% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 20
First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.04 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥84.4m (up 222% from 1Q 2020). Net income: CN¥36.0m (up CN¥32.6m from 1Q 2020). Profit margin: 43% (up from 13% in 1Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Mar 31
Full year 2020 earnings released The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: CN¥27.3k (down 100% from FY 2019). Net income: CN¥9.7k (down 100% from FY 2019). Profit margin: 35% (up from 34% in FY 2019). The increase in margin was driven by lower expenses. Is New 90 Day High Low • Feb 10
New 90-day high: CN¥224 The company is up 8.0% from its price of CN¥207 on 12 November 2020. The Chinese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is up 16% over the same period. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥162 The company is down 22% from its price of CN¥208 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 29
New 90-day low: CN¥164 The company is down 18% from its price of CN¥200 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥179 The company is down 19% from its price of CN¥220 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Aug 11
Eyebright Medical Technology (Beijing) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020 Eyebright Medical Technology (Beijing) Co., Ltd. announced that they will report first half, 2020 results on Aug 26, 2020